ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,321.41
0.25%
Dow Jones
39,872.99
0.17%
US Dollar vs MXN
16.60815
-0.08%
Brent Oil
81.965
-0.58%
Bitcoin
69,850.53
-0.40%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Legend Biotech Corporation (LEGN)

  7. Legend Biotech Corporation (LEGN) Noticias

LEGN

Legend Biotech (LEGN)

Legend Biotech Corporation
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:LEGN
FechaHoraFuenteTítuloSímboloCompañía
13/05/202406:10IH Market NewsU.S. Futures Climb Amid High Expectations for Inflation Data; Global Markets Show Mixed ReactionsNASDAQ:LEGNLegend Biotech Corporation
13/05/202406:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
13/05/202406:00Business WireLegend Biotech Reports First Quarter 2024 Results and Recent HighlightsNASDAQ:LEGNLegend Biotech Corporation
22/04/202412:05Business WireCARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple MyelomaNASDAQ:LEGNLegend Biotech Corporation
11/04/202407:00Business WireLegend Biotech to Host Investor Conference Call on First Quarter 2024 ResultsNASDAQ:LEGNLegend Biotech Corporation
05/04/202422:30Business WireLegend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple MyelomaNASDAQ:LEGNLegend Biotech Corporation
19/03/202407:30Business WireLegend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) ReportNASDAQ:LEGNLegend Biotech Corporation
15/03/202414:15Business WireCARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple MyelomaNASDAQ:LEGNLegend Biotech Corporation
11/03/202406:00Business WireLegend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent HighlightsNASDAQ:LEGNLegend Biotech Corporation
11/03/202405:39IH Market NewsU.S. Index Futures Dip Ahead of Inflation Data and Oracle’s Earnings; Oil Prices Edge HigherNASDAQ:LEGNLegend Biotech Corporation
28/02/202417:46Edgar (US Regulatory)Form 144/A - Report of proposed sale of securities: [Amend]NASDAQ:LEGNLegend Biotech Corporation
27/02/202418:47Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:LEGNLegend Biotech Corporation
23/02/202406:15Business WireLegend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of TherapyNASDAQ:LEGNLegend Biotech Corporation
14/02/202419:34Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:LEGNLegend Biotech Corporation
13/02/202407:00Business WireLegend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2023 ResultsNASDAQ:LEGNLegend Biotech Corporation
03/01/202410:28Business WireLegend Biotech Announces Closing of License Transaction for Certain CAR-T Therapies Targeting DLL3NASDAQ:LEGNLegend Biotech Corporation
02/01/202407:30Business WireLegend Biotech to Participate in the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:LEGNLegend Biotech Corporation
11/12/202318:30Business WirePatient-Reported Outcomes from the CARTITUDE-4 Study Showed Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Multiple Myeloma Symptoms Following Treatment with CARVYKTI® (ciltacabtagene autoleucel)NASDAQ:LEGNLegend Biotech Corporation
20/11/202305:25IH Market NewsMonday’s Wall Street Highlights: GM, Microsoft, Citigroup, Amazon, and moreNASDAQ:LEGNLegend Biotech Corporation
20/11/202305:00Business WireLegend Biotech Reports Third Quarter 2023 Results and Recent HighlightsNASDAQ:LEGNLegend Biotech Corporation
13/11/202308:16Dow Jones NewsLegend Biotech Subsidiary in License Agreement With NovartisNASDAQ:LEGNLegend Biotech Corporation
13/11/202307:30Business WireLegend Biotech Announces Exclusive, Global License Agreement for Certain CAR-T Therapies Targeting DLL3NASDAQ:LEGNLegend Biotech Corporation
07/11/202307:30Business WireLegend Biotech to Host Investor Conference Call on Third-Quarter ResultsNASDAQ:LEGNLegend Biotech Corporation
02/11/202308:17Business WireLegend Biotech to Showcase Leadership in Multiple Myeloma Treatment at the ASH 2023 Annual MeetingNASDAQ:LEGNLegend Biotech Corporation
15/08/202305:00Business WireLegend Biotech Reports Second Quarter 2023 Results and Recent HighlightsNASDAQ:LEGNLegend Biotech Corporation
03/08/202307:30Business WireLegend Biotech to Host Investor Conference Call on Second-Quarter ResultsNASDAQ:LEGNLegend Biotech Corporation
26/06/202309:31Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:LEGNLegend Biotech Corporation
06/06/202315:30Business WireLegend Biotech Announces Submission of Supplemental Application to the U.S. FDA for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel)NASDAQ:LEGNLegend Biotech Corporation
05/06/202310:18Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:LEGNLegend Biotech Corporation
05/06/202310:04Business WireCiltacabtagene Autoleucel (cilta-cel) Reduced Risk of Disease Progression or Death by 74% vs Standard Regimens for Adult Patients with Relapsed and Refractory Multiple Myeloma in CARTITUDE-4 StudyNASDAQ:LEGNLegend Biotech Corporation
 Showing the most relevant articles for your search:NASDAQ:LEGN

Su Consulta Reciente

ASX
IRI
Integrated Research
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados